company background image
I9SA logo

Verona Pharma DB:I9SA Stock Report

Last Price

€45.40

Market Cap

€3.6b

7D

17.6%

1Y

141.5%

Updated

30 Dec, 2024

Data

Company Financials +

Verona Pharma plc

DB:I9SA Stock Report

Market Cap: €3.6b

I9SA Stock Overview

A clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. More details

I9SA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Earnings are forecast to grow 72.83% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Significant insider selling over the past 3 months


My Notes

Capture your thoughts, links and company narrative

Verona Pharma plc Competitors

Dermapharm Holding

XTRA:DMP

€2.1b

Bayer

XTRA:BAYN

€19.0b

Merck KGaA

XTRA:MRK

€60.8b

PharmaSGP Holding

XTRA:PSG

€299.8m

Price History & Performance

Summary of share price highs, lows and changes for Verona Pharma
Historical stock prices
Current Share PriceUS$45.40
52 Week HighUS$46.20
52 Week LowUS$10.20
Beta0.43
1 Month Change19.47%
3 Month Change81.60%
1 Year Change141.49%
3 Year Change676.07%
5 Year Change900.00%
Change since IPO362.18%

Recent News & Updates

Recent updates

Shareholder Returns

I9SADE PharmaceuticalsDE Market
7D17.6%1.7%0.3%
1Y141.5%-16.3%6.9%

Return vs Industry: I9SA exceeded the German Pharmaceuticals industry which returned -16.3% over the past year.

Return vs Market: I9SA exceeded the German Market which returned 7.2% over the past year.

Price Volatility

Is I9SA's price volatile compared to industry and market?
I9SA volatility
I9SA Average Weekly Movement12.3%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.8%
10% least volatile stocks in DE Market2.4%

Stable Share Price: I9SA's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: I9SA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200579Dave Zaccardelliwww.veronapharma.com

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company’s product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler.

Verona Pharma plc Fundamentals Summary

How do Verona Pharma's earnings and revenue compare to its market cap?
I9SA fundamental statistics
Market cap€3.63b
Earnings (TTM)-€147.79m
Revenue (TTM)€5.41m

684.2x

P/S Ratio

-25.0x

P/E Ratio

Is I9SA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
I9SA income statement (TTM)
RevenueUS$5.62m
Cost of RevenueUS$543.00k
Gross ProfitUS$5.08m
Other ExpensesUS$158.80m
Earnings-US$153.72m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.88
Gross Margin90.35%
Net Profit Margin-2,733.34%
Debt/Equity Ratio92.0%

How did I9SA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 12:35
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Verona Pharma plc is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrick TrucchioBerenberg
Thomas ShraderBTIG
Edward NashCanaccord Genuity